Media

Zev A. Wainberg, Vincent Chung, et al.
Presented at the ASCO Gastrointestinal Cancer Symposium
January 18-20, 2024

CLINICAL TRIALS ARENA: The study aims to evaluate the antitumor activity of the vaccine in pancreatic ductal adenocarcinoma (PDAC) patients.

TARGETED ONCOLOGY: The first patient with KRAS-mutated pancreatic ductal adenocarcinoma (PDAC) has been dosed with ELI-002 7P in the phase 2 AMPLIFY-7P study (NCT05726864), according to Elicio Therapeutics, Inc.

MEDICAL NEWS TODAY: Researchers are reporting that a new vaccine could help prevent the reemergence of colorectal and pancreatic cancer in high-risk people who have previously undergone cancer treatment.

Shubham Pant, Zev A. Wainberg, et al.
Nature Medicine
January 09, 2024

INDEPENDENT: A new vaccine has shown “promising” signs of being able to prevent relapse of specific types of pancreatic and bowel cancers for people who have previously had surgery.

HEALTHDAY: Patients with the most common form of pancreatic cancer could benefit from an experimental therapeutic vaccine, a small new clinical trial shows.

PHARMA'S ALMANAC: In 2023, the FDA released the draft guidance titled: “Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products.” This draft guidance provides insight into the FDA’s expectations for cell and gene therapy (CGT) developers regarding manufacturing changes and comparability assessments under chemistry, manufacturing, and control (CMC) requirements.

LIFE SCIENCE LEADER: Ten years ago, Pete DeMuth was wrapping up his Ph.D. in biological engineering at MIT. In parallel, the lab at MIT was watering the sprout of a biotech business rooted in a simple hypothesis—the idea that precisely targeting vaccines to the right location in the body is critical for generating robust immunity against cancer.

TARGETED ONCOLOGY: Innovative findings in the field of cancer vaccines were presented at the Society for Immunotherapy of Cancer (SITC), focusing on a novel technology directing vaccines into lymph nodes.